Skip to main content
TipRanks
Go Ultimate75% OFF

Botanix Pharmaceuticals Limited (BOT) Share Price & Analysis

174 Followers

BOT Stock Chart & Stats

A$0.01A$0.00(0.00%)
At close: 4:00 PM GMT+11
AU$0.01AU$0.015AU$0.02Aug 17Aug 31Sep 14Sep 28Oct 12Oct 26Nov 9
Day’s Range
AUD 0.01 - AUD 0.01
52-Week Range
AUD 0.01 - AUD 0.15
Previous Close
AUD 0.01
Volume
N/A
Average Volume (3M)
9.48M
Market Cap
AUD 22.10M
Enterprise Value
AUD 34.48M
Total Cash (Recent Filing)
AUD 36.63M
Total Debt (Recent Filing)
AUD 14.74M
Price to Earnings (P/E)
―
Beta
1.04
Next Earnings
Mar 03, 2027 (Est.)
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Revenue Growth

Rapid revenue growth indicates increasing commercial traction and expanding demand for the company’s offerings. If this momentum persists, it could improve operating leverage, support broader market adoption, and provide a stronger foundation for eventually funding development from internal resources.

Reduced Debt

Debt reduction alongside a meaningful equity base improves financial flexibility and lowers leverage-related pressure. This gives the company more capacity to manage its clinical and regulatory activities, although continued losses could still reduce the strength of that cushion over time.

Focused Dermatology Pipeline

A focused topical dermatology strategy can concentrate scientific, clinical, and regulatory resources on a defined set of skin-disease opportunities. Prescription products addressing recognized dermatologic conditions could create durable commercial potential if development and regulatory preparation succeed.

Bears Say

Persistent Unprofitability

Persistent operating and net losses show that revenue growth has not yet translated into an economically sustainable business model. Deeply negative gross profit also raises uncertainty around margin durability, leaving the company dependent on future improvement in commercial performance and cost absorption.

Heavy Cash Burn

Large recurring cash outflows reduce the company’s ability to fund operations and development internally. Until revenue and margins improve materially, continued cash burn implies reliance on external funding, which can constrain strategic flexibility and increase financing pressure over the next several quarters.

Declining Equity Cushion

A shrinking equity base indicates that ongoing losses are consuming shareholder capital despite the remaining balance-sheet cushion. Strongly negative returns on equity further demonstrate inefficient capital use, potentially limiting the resources available for sustained investment in the pipeline.

Botanix Pharmaceuticals Limited News

BOT FAQ

What was Botanix Pharmaceuticals Limited’s price range in the past 12 months?
Botanix Pharmaceuticals Limited lowest share price was AU$0.01 and its highest was AU$0.15 in the past 12 months.
What is Botanix Pharmaceuticals Limited’s market cap?
Botanix Pharmaceuticals Limited’s market cap is AU$22.10M.
When is Botanix Pharmaceuticals Limited’s upcoming earnings report date?
Botanix Pharmaceuticals Limited’s next earnings report is estimated for Mar 03, 2027 (not yet confirmed), which is in 106 days.
How were Botanix Pharmaceuticals Limited’s earnings last quarter?
Botanix Pharmaceuticals Limited released its earnings results on Aug 26, 2026. The company reported -AU$0.01 earnings per share for the quarter.
Is Botanix Pharmaceuticals Limited overvalued?
According to Wall Street analysts Botanix Pharmaceuticals Limited’s price is currently Undervalued.
Does Botanix Pharmaceuticals Limited pay dividends?
Botanix Pharmaceuticals Limited does not currently pay dividends.
What is Botanix Pharmaceuticals Limited’s EPS estimate?
Botanix Pharmaceuticals Limited’s EPS estimate is -0.01.
How many shares outstanding does Botanix Pharmaceuticals Limited have?
Botanix Pharmaceuticals Limited has 2,762,671,100 shares outstanding.
What happened to Botanix Pharmaceuticals Limited’s price movement after its last earnings report?
Botanix Pharmaceuticals Limited reported an EPS of -AU$0.01 in its last earnings report. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Botanix Pharmaceuticals Limited?
Currently, no hedge funds are holding shares in AU:BOT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology